SANTA ANA, Calif. - NKGen Biotech, Inc. (NASDAQ: NKGN), a clinical-stage biotechnology company with a current market ...

The results from Phase 1 of the Troculeucel Clinical Trial demonstrated stable/improved outcomes in 90% of subjects, with no drug-related adverse ...

Unlike CAR-T cells, NK cells don’t need genetic modification to recognize a specific threat — they act broadly without customization. However, some NK companies, such as Fate Therapeutics and Cytovia ...

NK cell therapy is fast developing into a busy field, so it's something of a coup for Shoreline to forge an alliance with an established player like Gilead/Kite.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

University of Queensland research using natural killer cells may lead to the first new treatment for a devastating childhood ...

For the new therapy, these cells are derived from stem cells that originated from healthy adult donor tissue - called induced pluripotent stem cells (iPSCs) - to make therapeutic CAR-NK cells.

The Fast Track designation is supported by data from the open-label phase 1 SNK01-MX04 trial, as well as preliminary data from the phase 1 cohort from the phase 1/2a SNK01-AD01 trial.

It is the first comprehensive cellular analysis of ALS, carried out using single-cell RNA sequencing in 14 patients and 14 ...

Senti Bio aims to improve cancer therapeutics with customizable gene circuits, or multi-gene constructs capable of ...